Lanifibranor receive breakthrough designation in the US for non-alcoholic steatohepatitis (NASH)

Breakthrough designation for this investigational oral indole sulfonamide derivative anti-fibrotic was granted on the basis of a phase IIb trial demonstrating a statistically significant reduction in the Steatosis Activity Fibrosis score.

Source:

Biospace Inc.